International law firm McDermott Will & Emery represented Moffitt Cancer Center, a world leader in advancing cellular immunotherapies for the treatment of cancer, in its strategic alliance with Turnstone Biologics Corp., a clinical-stage biotechnology company developing next-generation immunotherapies to treat and cure solid tumors. Pursuant to this strategic alliance, which enhances and broadens the parties’ collaborative efforts to advance oncology research, Turnstone will have priority access to Moffitt’s scientific research, manufacturing, and clinical capabilities for the development of novel tumor infiltrating lymphocyte (TIL) therapies.

The parties also announced U.S. Food and Drug Administration clearance of an Investigational New Drug application for a Moffitt-sponsored Phase 1 clinical study of TIDAL-01, Turnstone’s lead TIL therapy candidate for cutaneous and non-cutaneous melanoma. The trial is expected to start late 2022.

The cross-border McDermott team includes Gary Davis, Jiayan Chen, Bob Louthian, Monika Richter and Richard Smith.

Read Moffitt’s press release.

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.